

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/748,703	12/30/2003	Jung San Huang	SLU 02-009	2134
33436 75 SAINT LOUIS U	590 04/04/200 INIVERSITY	7	EXAM	INER
OFFICE OF INNOVATION AND INTELLECTUAL PROPERTY		STOICA, ELLY GERALD		
3556 CAROLINE MALL SUITE C208			ART UNIT	PAPER NUMBER
ST. LOUIS, MO 63104				
SHORTENED STATUTORY	PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE	
31 DA	YS	04/04/2007	PAP	ER

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

·	Application No.	Applicant(s)	
	10/748,703	HUANG, JUNG SAN	
Office Action Summary	Examiner	Art Unit	
	Elly-Gerald Stoica	1647	
The MAILING DATE of this communication app Period for Reply		•	
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period w  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim rill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONEI	the mailing date of this communication (35 U.S.C. § 133).	•
Status			
1) Responsive to communication(s) filed on	_•		,
2a) This action is <b>FINAL</b> . 2b) ⊠ This	action is non-final.		
3)☐ Since this application is in condition for allowar			is
closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 45	3 O.G. 213.	
Disposition of Claims			
4)  Claim(s) <u>1-37</u> is/are pending in the application. 4a) Of the above claim(s) is/are withdray 5)  Claim(s) is/are allowed. 6)  Claim(s) is/are rejected. 7)  Claim(s) is/are objected to. 8)  Claim(s) <u>1-37</u> are subject to restriction and/or expending the application.	vn from consideration.		
Application Papers			
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) access Applicant may not request that any objection to the Replacement drawing sheet(s) including the correction of the original than 11) The oath or declaration is objected to by the Examine 10.	epted or b) objected to by the Edrawing(s) be held in abeyance. See on is required if the drawing(s) is obj	e 37 CFR 1.85(a). ected to. See 37 CFR 1.121	
Priority under 35 U.S.C. § 119	•		
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:  1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the prior application from the International Bureau * See the attached detailed Office action for a list of	s have been received. s have been received in Application ity documents have been received (PCT Rule 17.2(a)).	on No ed in this National Stage	
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO/SB/08)  Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal Pa	ite	

Application/Control Number: 10/748,703 Page 2

Art Unit: 1647

## **DETAILED ACTION**

## Election/Restrictions

1. This application contains claims directed to two categories of patentably distinct species:

- A. Fatty acids.
- B. Growth factors.

Within category A, there are two patentably distinct species:

- 1. Saturated fatty acids
- 2. Unsaturated fatty acids.

Within category B there are multiple patentably distinct species:

- I. platelet-derived growth factors,
- II. vascular endothelial cell growth factors,
- III. fibroblast growth factors,
- IV. interleukins,
- V. growth hormone,
- VI. insulin,
- VII. insulin-like growth factor-1,
- VIII. insulin-like growth factor-2,
- IX. nerve growth factor,
- X. neurotrophins and
- XI. TGF-β.

Art Unit: 1647

The species are independent or distinct because each of the members of the categories A and B has different structure, different biochemical and biological properties. The search for all the species disclosed would constitute an undue burden on the Examiner.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. For the response to be fully responsive it should contain one specie from group A (1 or 2) and one specie from group B (I-XI). Currently, claim 1 is generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Elly-Gerald Stoica whose telephone number is (571) 272-9941. The examiner can normally be reached on 8:30-17:00.

Application/Control Number: 10/748,703

Art Unit: 1647

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Brenda G. Brumback can be reached on (571) 272-0961. The fax phone

number for the organization where this application or proceeding is assigned is 571-

273-8300.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published

applications may be obtained from either Private PAIR or Public PAIR. Status

information for unpublished applications is available through Private PAIR only. For

more information about the PAIR system, see http://pair-direct.uspto.gov. Should you

have questions on access to the Private PAIR system, contact the Electronic Business

Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO

Customer Service Representative or access to the automated information system, call

800-786-9199 (IN USA OR CANADA) or 571-272-1000.

CHRISTINE J. SAOUD PRIMARY EXAMINER

Phristine J. Saouc

Page 4